Advertisement

  • Loading metrics

Open Access

Correction

Correction: Impairment of TrkB-PSD-95 Signaling in Angelman Syndrome

  • The PLOS Biology Staff
  • Article
  • Metrics
  • Comments
  • Media Coverage

JM wishes to declare the following competing interest, which should have been indicated in the research article. JM owned shares in Angelus Therapeutics. However, for clarification, no materials or support were received from this company, and no agreements were in place concerning the execution or publication of this work. In addition, a US patent application entitled “Long term potentiation with cyclic-GluR6 analogs” (US Patent Application #20120149646) has been filed by Brown University, with JM listed as co-inventor.

Reference

  1. 1. Cao C, Rioult-Pedotti MS, Migani P, Yu CJ, Tiwari R, et al. (2013) Impairment of TrkB-PSD-95 Signaling in Angelman Syndrome. PLoS Biol 11(2): e1001478

Citation: The PLOS Biology Staff (2014) Correction: Impairment of TrkB-PSD-95 Signaling in Angelman Syndrome. PLoS Biol 12(4): e1001848. https://doi.org/10.1371/journal.pbio.1001848

Published: April 8, 2014

Copyright: © 2014 The PLOS Biology Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.